The Benefits and Risks of Receiving Investigational Solid Tumor Drugs in Randomized Trials : A Systematic Review and Meta-analysis
CONCLUSION: Assignment to experimental groups produces statistically significant survival gains. However, the absolute survival gain is small, and toxicity is statistically significantly greater. The findings of this review provide reassuring evidence that patients are not meaningfully disadvantaged by assignment to comparator groups.PRIMARY FUNDING SOURCE: Canadian Institutes of Health Research.PMID:38684102 | DOI:10.7326/M23-2515
Source: Annals of Internal Medicine - Category: Internal Medicine Authors: Renata Iskander Hannah Moyer Dean Fergusson Sean McGrath Andrea Benedetti Jonathan Kimmelman Source Type: research
More News: Canada Health | Cancer | Cancer & Oncology | Internal Medicine | Statistics | Study | Toxicology